Previous 10 | Next 10 |
ROCHESTER, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that Maurice Zauderer, PhD, President and Chief Executive ...
Vaccinex (NASDAQ: VCNX ): Q2 GAAP EPS of -$0.77. More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019 Presented interim data from CLASSICAL-Lung study at the 2019 American Society of Clinical Oncology (ASCO) Annu...
Vaccinex ( VCNX -1.5% ) announces full enrollment (n=62) in a Phase 1b/2 clinical trial, CLASSICAL-Lung , evaluating lead candidate pepinemab (VX15/2503), combined with Pfizer's ( PFE +0.6% ) Bavencio (avelumab), in patients with advanced non-small cell lung cancer (NSCLC). Mor...
63% of evaluable subjects whose tumors had progressed during prior checkpoint inhibitor therapy benefited from treatment with the combination of pepinemab and avelumab Primary completion anticipated in second half of 2019 ROCHESTER, N.Y., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Vaccinex...
Ultra-thinly traded nano cap Vaccinex ( VCNX -9.2% ) is down on average volume, albeit on turnover of only 6K shares, in reaction to its private placement of ~3.4M common shares at $4.08 per share to a group of investors. More news on: Vaccinex, Inc., Healthcare stocks news, Stocks on ...
ROCHESTER, N.Y., July 31, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that the company entered into a stock purchase agreement pr...
The following slide deck was published by Vaccinex, Inc. in conjunction with this Read more ...
ROCHESTER, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim results of the Phase 1b/2 study of pep...
Vaccinex (NASDAQ: VCNX ): Q1 Revenue of $0.09M (-55.0% Y/Y) Cash and cash equivalents and marketable securities of $11.3M. Press Release More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, ,
News, Short Squeeze, Breakout and More Instantly...
Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, I...
A look at the top 10 most actives in the United States Novo Integrated Sciences Inc. (NVOS) rose 132.8% to $1.05 on volume of 308,155,573 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.9% to $0.0387 on volume of 278,348,616 shares Faraday Future Intelligent Electric Inc. (FFIE) ...
Vaccinex, Inc. (NASDAQ: VCNX) is one of today's top gainers. The company's shares have moved 15.16% on the day to $6. Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet...